Suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with high potency in inducing dierentiation of cultured murine erythroleukemia cells. We have recently demonstrated that SAHA induces cell cycle arrest and apoptosis in human breast cancer cells, accompanied by up-regulation of the cyclindependent kinase inhibitor, p21
Introduction
Suberoylanilide hydroxamic acid (SAHA) is a prototype of hydroxamic acid-based second generation hybrid polar compounds which are developed as cytodierentiating agents for potential cancer therapy (Richon et al., 1996) . SAHA is a potent inducer of terminal dierentiation of cultured murine erythroleukemia (MEL) cells (Richon et al., 1996) , and induces apoptosis in U937 human leukemia cells (Vrana et al., 1999) . In vivo studies show that SAHA inhibits the formation of carcinogen-induced tumors in animal models with low toxicity .
SAHA is a histone deacetylase (HDAC) inhibitor (Richon et al., 1998) . It is structurally related to another HDAC inhibitor, trichostatin A (TSA), a microbial metabolite originally used as an anti-fungal antibiotic (Yoshida et al., 1990) . SAHA and TSA inhibit HDACs by binding directly to the enzymes. The binding site of SAHA and TSA in Aquifex aeolicus HDAC homolog has recently been revealed to be an active site consisting of a tubular pocket, a zincbinding site and two Asp-His charge-relay systems, which are conserved across the HDAC family (Finnin et al., 1999) .
HDACs, together with the opposing enzymes, histone acetyltransferases (HATs), are involved in chromatin remodeling by modifying the acetylation states of histones. Histone acetylation by HATs mediates transcriptional activation by facilitating the binding of transcription factors to nucleosomal DNA (Struhl, 1998) , whereas histone deacetylation by HDACs results in transcriptional repression by restricting the access of transcription factors (Pazin and Kadonga, 1997; Wole, 1997) . Recent discoveries have identi®ed many transcription factors, coactivators, and basal transcription initiation complex proteins with intrinsic HAT activities (Kuo and Allis, 1998) . For HDACs, at least seven members have been identi®ed in human. By forming complexes with transcriptional repressors, corepressors, and other transcriptional factors, such as unliganded nuclear hormone receptors (Torchia et al., 1998) , SMRT (Nagy et al., 1997) , N-CoR (Alland et al., 1997; Heinzel et al., 1997) , the retinoblastoma protein (Rb) (Brehm et al., 1998; Magnaghi et al., 1998) , Max/Mad , MeCP2 (Jones et al., 1998; Nan et al., 1998) , YY1 (Yang et al., 1996) , and Sp1 (Doetzlhofer et al., 1999) , HDACs are involved in mediating various transcription regulatory pathways. Thus, they play important roles in controlling complex biological events including cell development, dierentiation and apoptosis.
Histone acetylation levels in cells are determined by a dynamic equilibrium between competing histone acetylases and deacetylases, and changes occur during both transcriptional activation and repression . Thus, by manipulating HAT or HDAC activities within cells, gene expression pro®les can be altered. One such an example is the use of HDAC inhibitors to activate the expression of certain genes. The anti-tumor activities observed with HDAC inhibitors such as SAHA and TSA suggest that antitumor genes associated with dierentiation, growth inhibition, and apoptosis are activated.
Studies with SAHA have primarily been performed with hematopoietic tumor cells. We have recently demonstrated that SAHA induced cell cycle arrest and apoptosis in human breast cancer cells, with lower toxicity to normal breast epithelial cells and ®broblasts (Huang and Pardee, 2000) . Moreover, SAHA-mediated cytotoxic eects on breast cancer cells were accompanied by hypophosphorylation of Rb, and induction of cyclin-dependent kinase (CDK) inhibitors, p21 WAF1/ CIP1 (p21) and p27 KIP1 (p27). Among those, p21 induction was the most prominent, since p21 was induced in all three human breast cancer cell lines tested, MCF7, MDA-MB-231 and MDA-MB-435 cells with dierent estrogen receptor (ER) and p53 status, whereas Rb hypophosphorylation and p27 induction by SAHA were cell type-dependent.
p21 may play an important role in mediating SAHAinduced eects on breast cancer cells. In this study, we further characterized SAHA-mediated p21 induction, and used the p21 promoter as a model system to elucidate the molecular mechanism(s) underlying SAHA-mediated gene activation. We demonstrated that SAHA induced p21 mRNA as an immediate-early gene in MCF7 cells and activated the p21 promoter primarily through two Sp1 sites located at 782 and 769 relative to the transcription start site. Moreover, SAHA did not alter the DNA binding activities of Sp1 and Sp3 transcription factors which were the major proteins binding to the Sp1 site of the p21 promoter. Furthermore, both GAL4-Sp1 and GAL4-Sp3 fusion proteins supported SAHA-mediated gene activation from a promoter driven by ®ve GAL4 DNA binding sites, and that GAL4-Sp3 fusion protein was suppressive in the absence of SAHA treatment. Taken together, our results suggest that SAHA activates the p21 promoter through the Sp1 sites, and that both Sp1 and Sp3 factors can mediate SAHA-induced gene activation.
Results

SAHA induces both p21 mRNA and protein expression
Previously, we demonstrated that p21 protein level was drastically induced by SAHA in human breast cancer cell lines in a p53-independent pathway. To determine if the induction is at the level of transcription, we analysed the eect of SAHA on p21 mRNA expression in MCF7 cells. As shown in Figure 1a , p21 mRNA was induced about twofold by SAHA (2 mM) as early as 2 h, reached its peak at 8 h (about 15-fold induction as compared to control), and was still induced throughout 24 h. Induction of p21 mRNA by SAHA was enhanced by concomitant treatment with the protein synthesis inhibitor, cycloheximide (50 mM), which alone enhanced p21 mRNA expression, indicating that SAHA induced p21 mRNA as a consequence of an immediate-early gene activation. p21 protein expression was also induced as early as 2 h, and continued to be induced throughout 24 h at which time the induction reached the highest levels ( Figure 1b) .
SAHA activates the p21 promoter through the Sp1 Sites
Since SAHA modulated p21 mRNA expression, we investigated if SAHA regulates p21 gene promoter activity. We used transient transfection and luciferase assays with full-length p21 promoter-luciferase reporter plasmid (pWWP) and a series of mutated constructs as diagramed in Figure 2a Treatment of MCF7 cells with SAHA at 2 mM activated the full-length promoter pWWP only by about 1.6-fold over the control at 24 h post-treatment and approximately fourfold over the control at 48 h post-treatment (Figure 2b,c) . However, deletion of the In some experiments, cells were pretreated with cycloheximide at 50 mM for 1 h, and then treated with or without SAHA for 24 h. After treatment, cells were analysed for p21 mRNA expression by Northern blot analysis. Probing with GAPDH was used to normalize the amount of loaded RNA. The Northern blots were autoradiographed with intensifying screens for 20 h (p21) or 8 h (GAPDH). Autoradiographs were scanned using a densitometer, and band intensity was quanti®ed using Molecular Analyst program. Background values were subtracted out from all readings. The intensity ratios, which are shown at the bottom of the picture, were calculated by dividing the intensity of p21 band to that of the corresponding GAPDH band. (b) SAHA-mediated p21 protein induction parallels p21 mRNA induction. MCF7 cells were treated with DMSO alone or SAHA at 2 mM for 2, 4, 8 or 24 h, and then analysed for protein expression by Western blot analysis. The same blot was probed with actin as a loading control Oncogene Sp1/Sp3 mediates SAHA-induced gene activation L Huang et al region from positions 72326 to 7133 allowed the activation by SAHA to be dramatically increased, as demonstrated by the activation of pWPdel-BstX1 by about 11-fold over the control at 24 h and about 26-fold over the control at 48 h. That the activation of pWPdel-BstX1 by SAHA was much higher than that of pWWP also suggests that other regulatory elements exist within the region between 72326 and 7133. Of note, TSA, a speci®c HDAC inhibitor, activates the p21 promoter in human osteosarcoma cell line MG63 in a similar pattern as SAHA . It is also of interest to note that Smad3/Smad4, the signal transducers of the transforming growth factor b (TGFb), activate the p21 promoter in a way similar to SAHA (Moustakas and Kardassis, 1998) . Like SAHA, both TSA and Smad3/Smad4 activate the promoter from 7133 to the start site much more strongly than the promoter from 72326 to the start site, suggesting the existence of possible common regulatory elements within the region between 72326 and 7133.
pWPdel-BstX1 lacks the two p53 binding sites, yet was strongly activated by SAHA, indicating that SAHA activates the p21 promoter in a p53-independent pathway, consistent with p21 induction in cell lines with mutant p53 (Huang and Pardee, 2000) .
The 133-bp promoter segment in the pWPdel-BstX1 construct spans six Sp1 binding sites (Figure 2a ). Sp1-1, Sp1-2, Sp1-3, and Sp1-4 are independent binding sites, whereas Sp1-5 and Sp1-6 are overlapping binding sites. Deletion of the Sp1-1 and Sp1-2 sites from positions 7133 to 7101 (pWP101) caused less than twofold reduction of the basal promoter activity at 24
Figure 2 SAHA activates the p21 promoter through the Sp1 sites. (a) Schematic representation of p21 promoter-luciferase reporter plasmids: pWWP containing the full length promoter; pWPdel-BstX1, pWP101 and pWPdel-SmaI containing a series of deleted promoters; pWP101-mtSp1-3, pWP101-mtSp1-4, and pWP101-mtSp1-5,6 containing the promoter segment in pWP101 with respective Sp1 sites mutated; Sp1-luc and mtSp1-luc containing TATA-less promoter driven by three consensus Sp1 sites and mutated Sp1 sites, respectively. The circles represent the locations of Sp1 sites, and the crosses indicate mutations within the Sp1 sites. LUC represents the luciferase reporter gene. The transcription start site is indicated by +1. The locations of the 5' ends of the promoters are indicated by the negative numbers of nucleotides relative to the start site. (b,c) Transient transfection and luciferase assays of p21 promoter reporter plasmids. MCF7 cells were transfected with the reporter constructs, 24 h later, treated with DMSO alone or SAHA at 2 mM for 24 h (b), or 48 h (c), and then analysed for luciferase activities. (d) Transient transfection and luciferase assays of Sp1-luc and mtSp1-luc plasmids. MCF7 cells were transfected, and treated with DMSO alone or SAHA at 2 mM for 24 h, and then analysed for luciferase activities. The luciferase units produced from transfected cells treated with SAHA (®lled bars) and without SAHA (open bars) were plotted. The number given after times symbol`6' at the top of each ®lled bar represents fold activation by SAHA in cells transfected with individual plasmid. Shown are representative data from three independent experiments. Repeated experiments produced similar promoter activation pattern after treatment with SAHA. For example, at 24 h posttreatment, the fold activation by SAHA ranged from 1.6 to 2.2 for pWWP, 11.2 to 15.4 for pWPdel-BstXI, 12.6 to 16.5 for pWP101, 1 to 1.4 for pWP101-mtSp1-3, 2.6 to 3.5 for pWP101-mtSp1-4, 0.5 to 1.3 for pWP101-mtSp1-5,6, 1.2 to 1.8 for pWPdelSmaI, 6 to 10.6 for Sp1-luc, and 1.9 to 3 for mtSp1-luc and 48 h (Figure 2b,c) . Likewise, deletion of Sp1-1 and Sp1-2 sites did not signi®cantly aect SAHA-mediated activation of the promoter, since SAHA still activated pWP101 by about 15-fold over the control at 24 h and 17.5-fold over the control at 48 h. In contrast, deletion of the Sp1-3 and Sp1-4 sites from positions 7101 to 760 (pWPdel-SmaI) caused a further 15-and 24-fold reduction of the basal promoter activity at 24 and 48 h respectively, suggesting that the region containing the Sp1-3 and Sp1-4 sites are important for the basal promoter activity. Similarly, deletion of Sp1-3 and Sp1-4 sites from pWP101 caused a dramatic reduction of SAHA-mediated activation, which was reduced from approximately 15-fold in pWP101 to 1.4-fold over the control in pWPdel-SmaI at 24 h, and from 17.5-fold in pWP101 to ninefold over the control in pWPdel-SmaI at 48 h, suggesting that Sp1-3 and Sp1-4 sites play regulatory roles in SAHA-mediated activation of the p21 promoter.
To further de®ne SAHA-responsive elements, we tested a series of pWP101 promoter constructs with the respective Sp1 site mutated (Figure 2b,c) . In SAHAtreated MCF7 cells, the luciferase activity from pWP101-mtSp1-3 in which the Sp1-3 site was mutated from the wild-type CCCGCC to CAAAAC was similar to the control at 24 h. Even at 48 h, the activation by SAHA was reduced from 17.5-fold in pWP101 to about threefold over the control in pWPd101-mtSp1-3. When the Sp1-4 site was mutated from wild-type GGCGGG to GTTTTG, the activation by SAHA was reduced from about 15-fold in pWP101 to threefold over the control in pWP101-mtSp1-4 at 24 h, and from 17.5-fold in pWP101 to about 12-fold over the control in pWP101-mtSp1-4 at 48 h. These results indicate that Sp1-3 and Sp1-4 sites are important responsive elements for SAHA-mediated activation. Sp1-3 and Sp1-4 sites are also important transcription regulatory elements for the basal promoter activity, since mutation of the Sp1-3 site or the Sp1-4 site in pWP101 caused approximately 5 ± 7-fold reduction of the basal promoter activity at 24 and 48 h.
When the overlapping Sp1-5,6 sites were mutated from GGGCGGGGCGG to GGTTTTGGCGG, SAHA did not activate the promoter at all at either 24 or 48 h, since the basal promoter activity of pWP101-mtSp1-5,6 was reduced to the background level, suggesting that Sp1-5,6 sites are indispensable for p21 basal promoter activity.
Taken together, these results indicate that the Sp1-3 site located between 782 and 777 relative to the transcription start site is the primary SAHA responsive element, and that the Sp1-4 site located between 769 and 764 is at least partially involved in SAHAmediated activation. Additionally, our results demonstrate that the full basal promoter activity requires both the distal and proximal promoter regions, and that the Sp1-5,6 sites located between 760 and 750 is indispensable for the basal p21 promoter activity.
To demonstrate that the Sp1 sites are truly elements activated by SAHA, we tested the ability of SAHA to activate the luciferase reporter construct Sp1-luc containing a TATA-less promoter driven by three consensus Sp1 binding sites, and the mutant Sp1-luc with mutated Sp1 sites. As shown in Figure 2d , Sp1-luc was markedly activated by SAHA by about sevenfold over the control, whereas mtSp1-luc was only slightly activated by approximately twofold over the control, supporting that SAHA activates the promoter primarily through the Sp1 sites.
SAHA does not alter the DNA binding activities of Sp1 and Sp3 proteins
To determine if SAHA may aect the protein-DNA binding activities within the responsive element, we applied EMSA using annealed oligonucleotides spanning the Sp1-3 site, between positions 787 and 772 relative to the transcription start site. As shown in Figure 3 , with MCF7 cell nuclear extract, we detected three distinct protein-DNA binding complexes which were readily competed by a 100-fold excess of unlabeled wild-type Sp1 oligonucleotides but not by the same fold excess of the unlabeled oligonucleotides with mutated Sp1 site, indicating that these three complexes contained speci®c proteins binding to the Sp1 site. Supershift assays using speci®c antibodies to Sp1 and Sp3 demonstrated that the slowest migrating complex was markedly reduced and a supershifted band was observed in the presence of anti-Sp1 antibody (Figure 3, lane 4) , whereas the second-and third-slowest migrating complexes were markedly reduced and a supershifted band was observed in the presence of anti-Sp3 antibody (Figure 3, lane 6 ). In the presence of both anti-Sp1 and anti-Sp3 antibodies, all three complexes were markedly reduced and a supershifted band was observed (Figure 3, lane 7) . To demonstrate the speci®city of these antibodies, normal Figure 3 SAHA does not alter DNA-binding activities of Sp1 and Sp3. Nuclear extracts were prepared from MCF7 cells treated with DMSO alone (Control) or SAHA at 2 mM for 24 h, and subjected to EMSA using a labeled oligonucleotide probe spanning the Sp1-3 site of the p21 promoter. In some reaction mixtures, a 100-fold excess of unlabeled wild-type Sp1 (wt Sp1; lane 2) or mutant Sp1 (mt Sp1; lane 3) oligonucleotides was added, as competitors. Speci®c antibodies were added in the following reactions: lanes 4 and 9, anti-Sp1 antibody; lanes 6 and 10, anti-Sp3 antibody; lanes 7 and 11, both anti-Sp1 and anti-Sp3 antibodies. Addition of normal rabbit IgG was used as a negative control (lane 5). Lanes 1 and 8: no competitors or antibodies added. The free probe, the speci®c complexes containing respective Sp1 and Sp3 factors, and the supeshifted complexes were indicated by arrows Oncogene Sp1/Sp3 mediates SAHA-induced gene activation L Huang et al rabbit IgG was used in the supershift assays. As expected, all three complexes were not altered in the presence of normal rabbit IgG (Figure 3, lane 5) . Taken together, these results indicated that the slowest migrating complex contained Sp1 transcription factor, whereas the second-and third-slowest migrating complexes contained Sp3 factor. These Sp1 and Sp3 binding complexes were also detected with nuclear extracts prepared from SAHAtreated MCF7 cells (Figure 3, lanes 8 ± 9) . Moreover, treatment with SAHA (2 mM) for 24 h did not alter the DNA binding activities of Sp1 and Sp3 (compare lane 1 and lane 8 in Figure 3 ), suggesting that SAHA mediates p21 promoter activity by a mechanism other than changing the DNA binding activities of Sp1 and Sp3.
Both Sp1 and Sp3 mediate SAHA-induced gene activation
To determine if Sp1 and Sp3 mediate SAHA-induced gene activation, we used a luciferase reporter system in which Sp1 or Sp3 was fused to the DNA binding domain of the bacterial transcription factor GAL4 and the abilities of the fusion proteins to transactivate a promoter driven by ®ve consensus GAL4 DNA binding sites in the presence and absence of SAHA could be measured. The plasmid expressing either GAL4-Sp1 fusion protein or GAL4-Sp3 fusion protein was cotransfected into MCF7 cells with the luciferase reporter plasmid containing the GAL4 binding sites, and the transfected cells were subsequently treated with or without SAHA (2 mM). After 24 h treatment, cells were assayed for luciferase activities. As shown in Figure 4 , after 24 h treatment, SAHA activated the reporter plasmid alone (Control) by about fourfold, and the reporter plasmid co-transfected with the plasmid expressing only the GAL4 binding domain (GAL4) by about 16-fold. When the reporter plasmid was cotransfected with the plasmid expressing either GAL4-Sp1 or GAL4-Sp3 fusion protein, SAHA strongly activated the promoter by about 55 and 47-fold respectively. These results suggest that GAL4-Sp1 and GAL4-Sp3 fusion proteins supported SAHAmediated promoter activation.
Sp3 is suppressive in the absence of SAHA treatment
We have demonstrated that both Sp1 and Sp3 acted as positive regulators for SAHA-mediated promoter transactivation. However, in the absence of SAHA treatment, Sp3 acted as a negative regulator, as demonstrated in Figure 5 . Cotransfection of the reporter plasmid with the plasmid expressing GAL4-Sp3 fusion protein resulted in about 10-fold reduction of the luciferase avtivity, whereas cotransfection with the plasmid expressing just the GAL4 DNA binding domain or with the plasmid expressing GAL4-Sp1 fusion protein resulted in only slight reduction (less than twofold) of the luciferase activity, and the fold reduction induced by GAL4-Sp1 was similar to that by GAL4 alone. These results suggest that Sp3 was suppressive in the absence of SAHA treatment.
Discussion
In this study, we report that SAHA induced p21 mRNA as a consequence of an immediate early gene activation in MCF7 cells and activated the p21 promoter primarily through two Sp1 sites located at 782 and 769 relative to the transcription start site, in a p53-independent manner. The primary SAHAresponsive element is the Sp1-3 site located between 782 and 777 relative to the transcription start site. In addition, the Sp1-4 site located between 769 and 764, at least partially contributes to SAHA-mediated activation of the p21 promoter. Not surprisingly, the Sp1-3 and Sp1-4 sites are also the responsive elements of other HDAC inhibitors, such as butyrate and TSA, for activation of the p21 promoter (Nakano et al., Figure 4 Both Sp1 and Sp3 mediate SAHA-induced promoter activation. MCF7 cells were transfected with the GAL4 luciferase reporter construct pG5-luc alone (Control), or plus plasmid pM expressing the GAL4 DNA binding domain (GAL4) or pM-Sp1 expressing GAL4-Sp1 fusion protein (GAL4-Sp1) or pM-Sp3 expressing GAL4-Sp3 fusion protein (GAL4-Sp3). Transfected cells were treated with DMSO alone or SAHA at 2 mM for 24 h and then analysed for luciferase activities. The fold induction by SAHA was obtained by dividing the mean luciferase activity of SAHA-treated samples by the mean luciferase activity of DMSOtreated samples. The standard deviations from three independent experiments were shown 1997; Sowa et al., 1997) . Interestingly, the region containing the responsive elements for HDAC inhibitors also mediates p21 transcriptional activation regulated by TGF-b (Datto et al., 1995) , the protein kinase C activator phorbol esters (Biggs et al., 1996) , the phosphatases 1 and 2A inhibitor okadaic acid (Biggs et al., 1996) , the geranylgeranyltransferase I inhibitor GGTI-298 (Adnane et al., 1998) , progesterone (Owen et al., 1998) , and nerve growth factor (Billon et al., 1999) . We have then demonstrated that Sp1 and Sp3 transcription factors bind speci®cally to the Sp1-3 site of the p21 promoter, the primary SAHA-responsive element. However, SAHA did not alter the DNA binding activities of Sp1 and Sp3. This is consistent with the eects of other inducers such as TGF-b, phorbol esters, butyrate, and TSA (Biggs et al., 1996; Datto et al., 1995; Nakano et al., 1997; Sowa et al., 1997 Sowa et al., , 1999 , suggesting that these inducers mediate p21 promoter activity by a mechanism other than alteration of the DNA binding activities of Sp1 and Sp3. The mechanism could be through modifying Sp1 and/or Sp3, altering their interaction with other proteins, or aecting proteins directly or indirectly interacting with Sp1 and/or Sp3.
Using a GAL4 luciferase assay system, we demonstrated that both Sp1 and Sp3 mediate SAHA-induced gene activation. This is dierent from the results with TSA in human osteosarcoma cell line MG63, which demonstrate that Sp3 but not Sp1 mediates TSAinduced gene activation (Sowa et al., 1999) . Such dierence may be due to dierent compounds, dierent cell systems used, or dierent mechanisms. In murine NIH3T3 cells, however, both Sp1 and Sp3 are responsible for TSA-mediated mouse p21 promoter activation (Xiao et al., 1999) , which is consistent with our results. In contrast to the results with TSA in MG63 cells, the results with TGF-b show that Sp1 but not Sp3 is responsible for TGF-b-mediated promoter activation (Li et al., 1998) . Sp1 also mediates progesterone-induced p21 promoter activation, in which CBP/p300 is involved as well (Owen et al., 1998) . Overall, Sp1 and Sp3 can be dierentially involved in promoter activation mediated by p21 inducers, depending on dierent inducers and cell systems.
Sp1 is largely described as a positive transcription regulator. Physical and functional association of Sp1 with transcriptional coactivator p300, a histone acetytransferase, has recently been demonstrated (Billon et al., 1999; Suzuki et al., 2000; Xiao et al., 2000) . However, Sp3 and several internally initiated Sp3 proteins have been shown to primarily function as transcription repressors Kennett et al., 1997; Majello et al., 1994) . Our result that Sp3 was suppressive in the absence of SAHA treatment is consistent with the negative role of Sp3. Upon SAHA treatment, however, Sp3 became a positive regulator. Based on our results and recent studies showing direct interaction between HDAC1 and Sp1 or Sp3 (Doetzlhofer et al., 1999) , an attractive model could be proposed for SAHA-mediated promoter activation. In this model, SAHA activates promoter activity by inhibiting HDACs recruited to the Sp1 site by Sp1 and Sp3. In the absence of SAHA treatment, association of Sp3 with HDAC makes Sp3 suppressive.
The activity of Sp1 might be determined by the dynamic equilibrium between competing of its associated HATs and HDACs. Upon treatment with SAHA which inhibits HDAC activity, both Sp1 and Sp3 become strong positive regulators. This model remains to be tested.
In summary, our results demonstrated that SAHA induced p21 mRNA as an immediate-early gene in MCF7 cells and activated the p21 promoter primarily through two Sp1 sites located at 782 and 769 relative to the transcription start site, in a p53-independent manner. Moreover, Sp1 and Sp3 were the major factors binding to the Sp1 site of the p21 promoter, and that SAHA did not alter their DNA binding activities. Furthermore, both Sp1 and Sp3 mediated SAHA-induced gene activation, and Sp3 was suppressive in the absence of SAHA treatment. Taken together, our results suggest that SAHA activates the p21 promoter through the Sp1 sites, and that both Sp1 and Sp3 can mediate SAHA-induced gene activation. This activation of p21, independent of p53, thus may be caused by a histone acetylation mechanism. This acetylation-dependent mechanism could account for the often observed induction of p21 in cells lack of functional p53.
Materials and methods
Cell culture
Human breast cancer cell line MCF7 was kindly provided by Dr Beverly Teicher. Cells were grown in DMEM medium supplemented with 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml) at 378C in a humidi®ed incubator with 5% CO 2 .
Chemicals
SAHA was generously provided by Drs Victoria M Richon and Paul A Marks (Memorial Sloan-Keterring Cancer Center) (Richon et al., 1996) . SAHA was dissolved in DMSO at a concentration of 20 mM and stored in small aliquots at 7708C. When in use, the compound was ®rst diluted in medium and then added into the culture. Cycloheximide was obtained from Sigma (St. Louis, MO, USA), and was dissolved in ethanol at a stock solution of 500 mM.
Western blot analysis
Western blot analysis was carried out as described previously (Huang and Pardee, 2000) . Brie¯y, total protein extracts were prepared from MCF7 cells treated with SAHA (2 mM) or DMSO alone for 2, 4, 8 and 24 h, and 40 mg of protein per lane was resolved by 12% SDS polyacrylamide gel electrophoresis (SDS ± PAGE) and transferred to a nitrocellulose membrane. The blot was probed with rabbit polyclonal antibody to p21 (Cat.# sc-397; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by horseradish peroxidase (HRP)-conjugated secondary goat anti-rabbit antibody (Cat.# sc-2004; Santa Cruz). Proteins were detected using the ECL chemiluminescence detection system (Amersham Corp., Little Chalfont, UK). The blot was subsequently stripped and reprobed with rabbit polyclonal antibody to actin (Cat.# A-2066; Sigma), which served to normalize the amount of loaded protein.
Northern blot analysis
Cells were treated with SAHA (2 mM) or DMSO alone for 2, 4, 8 and 24 h. For some experiments, cells were pretreated Oncogene Sp1/Sp3 mediates SAHA-induced gene activation L Huang et al with cycloheximide at 50 mM for 1 h prior to addition of SAHA. After treatment, cells were harvested, and total cellular RNA was prepared by using Trizol reagent (Gibco BRL, Grand Island, NY, USA). Twenty mg of total RNA per lane was fractionated by electrophoresis through a 1% agarose/2M formaldehyde gel, and then transferred to a nylon membrane. The blot was prehybridized for 30 min at 688C in ExpressHyb hybridization solution (Clontech, Palo Alto, CA, USA), and then hybridized for 1 h at 688C in fresh ExpressHyb solution containing a-32 P-dCTP-labeled p21 probe (1610 6 c.p.m./ml) prepared from a p21 expression vector using a random primed DNA labeling kit (Boehringer Mannheim, Minneapolis, MN, USA). After hybridization, the blot was washed with 26SSC (16SSC is 0.15 M NaCl and 0.015 M sodium citrate) plus 0.05% SDS for 40 min at room temperature, and with 0.16SSC plus 0.1% SDS for 40 min at 508C. The washed blot was exposed to Kodak X-AR ®lm for detection of annealed probe. The same blot was subsequently stripped and rehybridized with a-32 P-dCTPlabeled glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe, to normalize the amount of loaded RNA. The GAPDH probe was prepared from a cDNA fragment which was obtained by RT ± PCR using the following primer pair: 5'-ACCACAGTCCATGCCATCAC-3' and 5'-TCCACCACCC-TGTTGCTGTA-3'.
Electrophoretic mobility shift assay (EMSA)
Complementary oligonucleotides (5'-AGCTCGGGTCCCG-CCTCCTT-3' and 5'-TCGAAAGGAGGCGGGACCCG-3') containing the sequences from 787 to 772 relative to the transcription start site of the p21 promoter were annealed, and labeled with [g-32 P]ATP by T4 polynucleotide kinase. Nuclear extracts were prepared from MCF7 cells treated with SAHA (2 mM) or DMSO for 24 h, as described elsewhere (Dignam et al., 1983) . Ten mg of nuclear extract was incubated in reaction mixture containing HEPES buer (20 mM, pH 7.9), MgCl 2 (5 mM), KCl (120 mM), DTT (1 mM), Triton X-100 (0.1%), glycerol (10%), poly(dI´dC) (1 mg/ml), and 32 P-end-labeled probe (5610 4 c.p.m., 0.02 pmol). In the reaction mixtures for competition assays, a 100-fold excess of unlabeled wild-type oligonucleotides or mutant oligonucleotides with the Sp1 site mutated (5'-AGCTCGGGTCAAAACTCCTT-3' and 5'-TCGAAAG-GAGTTTTGACCCG-3') was added. The reaction mixtures were incubated at room temperature for 15 min, and further incubated for 20 min in the presence or absence of speci®c polyclonal antibodies against Sp1 (Cat.# sc-59X) or Sp3 (Cat.# sc-644X), or normal rabbit IgG (Cat.# sc-2027), purchased from Santa Cruz Biotechnology. The protein-DNA complexes were resolved on a 5% non-denaturing polyacrylamide gel with 0.56TBE buer. The gel was then dried and exposed to an X-ray ®lm.
Plasmids
The full-length human p21 promoter-luciferase reporter construct pWWP, a series of mutant p21 promoter constructs including pWPdel-BstX1, pWP101, pWP101-mtSp1-3, pWP101-mtSp1-4, pWP101-mtSp1-5,6 and pWPdel-SmaI, as well as the luciferase-reporter plasmid Sp1-luc and the mutant Sp1-luc were generated as described previously Sowa et al., 1997) . Sp1-luc contains the promoter driven by three consensus Sp1 binding sites from the SV40 promoter, whereas mtSp1-luc contains three mutant Sp1 sites. The plasmids pM, pM-Sp1, pM-Sp3, and pG5-luc, which were used in the GAL4 luciferase assay system, were constructed as described previously (Sowa, 1999) . pM-Sp1 and pM-Sp3 express fusion proteins in which the GAL4 DNA binding domain was fused to active forms of Sp1 (amino acids 83 ± 778) and Sp3 (amino acids 1 ± 654), respectively. pM only expresses the GAL4 DNA binding domain. pG5-luc expresses the luciferase reporter gene driven by ®ve consensus GAL4 DNA-binding sites upstream of the E1B minimal promoter and a TATA box.
Transfection and luciferase assay MCF7 cells were plated into 6-well plates at a density of 2610 5 per well, and incubated for 24 h. For p21 promoter analysis, cells were transfected with 1 mg per well of p21 promoter reporter plasmid DNA by using Fugene 2 6 transfection reagent (Boehringer Mannheim). For the GAL4 luciferase assay system, cells were transfected with 1 mg per well of the luciferase reporter plasmid pG5-luc alone or plus 1 mg per well of pM, pM-Sp1 or pM-Sp3. After 24 h incubation, the transfected cells were treated with SAHA (2 mM) or DMSO alone. Following 24 or 48 h treatment, cells were lysed and assayed for luciferase activities, using the Promega luciferase assay system (Promega, Madison, WI, USA). Luciferase activities were measured by using a luminometor (Model: Lumat LB9507; EG&G Berthold, Germany). Protein concentrations in cell lysates were measured using the BioRad protein assay reagent, to normalize the luciferase activities among samples. Transfections were done in duplicate, and repeated three times.
